Two months after Allogene abandoned plans for its CAR-T in leukemia, analysts have suggested that fresh phase 1 data in ...
Shares of US clinical-stage biotech Allogene Therapeutics rocketed 41% to $1.99 on Friday, as it announced the publication of ...
In a report released today, Biren Amin from Piper Sandler maintained a Buy rating on Allogene Therapeutics (ALLO – Research Report), with a ...
Allogene Therapeutics (ALLO) announced the publication of data from its Phase 1 ALPHA and ALPHA2 clinical studies of cemacabtagene ...
Allogene Therapeutics Inc (NASDAQ:ALLO). shares have tumbled to a 52-week low, with the stock price touching down at $1.33. According to InvestingPro data, the stock appears undervalued, with analyst ...
SOUTH SAN FRANCISCO - Allogene Therapeutics, Inc. (NASDAQ:ALLO), a biotechnology firm specializing in allogeneic CAR T therapies currently valued at approximately $299 million, has published new data ...
SOUTH SAN FRANCISCO, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ALLO), a clinical-stage biotechnology company ...
The U.S. Food and Drug Administration (FDA has cleared the investigational new drug (IND) application for Allogene ...
SOUTH SAN FRANCISCO, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T ...
SOUTH SAN FRANCISCO, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback